(0.34%) 5 117.21 points
(0.34%) 38 369 points
(0.39%) 15 989 points
(-0.94%) $83.06
(5.25%) $2.02
(0.34%) $2 355.20
(0.54%) $27.68
(4.12%) $960.05
(-0.29%) $0.932
(-0.47%) $10.97
(-0.58%) $0.796
(1.66%) $93.40
@ $54.30
発行日: 26 4月 2024 @ 22:49
リターン: 1.80%
前回のシグナル: 4月 26 - 22:32
前回のシグナル:
リターン: 1.93 %
Live Chart Being Loaded With Signals
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform...
Stats | |
---|---|
本日の出来高 | 771 493 |
平均出来高 | 1.72M |
時価総額 | 4.69B |
EPS | $0 ( 2024-02-20 ) |
次の収益日 | ( $-1.630 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -28.49 |
ATR14 | $1.500 (2.72%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Kulkarni Samarth | Buy | 19 582 | Common Shares |
2024-04-15 | Kulkarni Samarth | Sell | 18 378 | Common Shares |
2024-04-15 | Kulkarni Samarth | Sell | 1 204 | Common Shares |
2024-04-15 | Kulkarni Samarth | Sell | 19 582 | Stock Option (Right to Buy) |
2024-03-20 | Kasinger James R. | Buy | 33 333 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
63.61 |
Last 100 transactions |
Buy: 2 415 277 | Sell: 542 570 |
ボリューム 相関
CRISPR Therapeutics AG 相関
10 最も負の相関 | |
---|---|
CFV | -0.899 |
SITM | -0.896 |
AMRB | -0.896 |
MTSI | -0.885 |
EVBG | -0.883 |
ASRVP | -0.881 |
GMII | -0.88 |
PSCC | -0.88 |
MMAC | -0.879 |
PEBK | -0.872 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
CRISPR Therapeutics AG 相関 - 通貨/商品
CRISPR Therapeutics AG 財務諸表
Annual | 2023 |
収益: | $370.00M |
総利益: | $239.75M (64.80 %) |
EPS: | $-1.940 |
FY | 2023 |
収益: | $370.00M |
総利益: | $239.75M (64.80 %) |
EPS: | $-1.940 |
FY | 2022 |
収益: | $436 000 |
総利益: | $-109.81M (-25 186.70 %) |
EPS: | $-8.36 |
FY | 2021 |
収益: | $914.96M |
総利益: | $914.96M (100.00 %) |
EPS: | $4.97 |
Financial Reports:
No articles found.
CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。